TetraLogic Pharmaceuticals Announces Preclinical Data Indicating Birinapant's Breadth of Activity in Models of Infectious Dis...
June 09 2014 - 6:30AM
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today
announced results from its collaboration with the Walter and Eliza
Hall Institute of Medical Research, Melbourne, Australia,
indicating that SMAC mimetics, including TetraLogic's lead compound
birinapant, may have broad applicability in the treatment of
infectious disease.
Previous preclinical studies performed at the Walter and Eliza
Hall Institute have indicated that birinapant decreases the viral
burden in mice infected with human hepatitis B virus (HBV) by
inducing apoptosis of virally infected liver cells resulting in the
reduction of circulating HBV and surface antigen (HBsAg). Recent
studies have extended these findings and indicate that other novel
SMAC mimetics from TetraLogic's library share this activity in
HBV.
Birinapant has also indicated activity in other models of
infectious disease; specifically, it induces cell death in human
blood cells infected with Human Immunodeficiency Virus, decreases
the bacterial burden in the lungs of mice infected with
tuberculosis and in mice infected with Legionella.
TetraLogic has entered into a license agreement with the Walter
and Eliza Hall Institute for worldwide exclusive rights to a patent
application relating to a method of treating intracellular
infections with administration of an inhibitor of the Inhibitor of
Apoptosis (IAP) proteins.
"We are delighted with the progress of this research
collaboration," said institute director Professor Doug Hilton, "and
we are looking forward to the initiation of clinical studies based
on this work."
"These results further support the fundamental mechanism by
which SMAC mimetics are operating, and provide additional rationale
for the study of birinapant in infectious disease," said Dr. Glenn
Begley, TetraLogic's Chief Scientific Officer.
About the Walter and Eliza Hall Institute
The Walter and Eliza Hall Institute is Australia's oldest
medical research institute. It is home to almost 750 researchers
who are working to understand, prevent and treat diseases including
infectious diseases, cancers and immune disorders. It is located in
Parkville, Melbourne, and is closely associated with The University
of Melbourne and The Royal Melbourne Hospital.
About Birinapant
Birinapant (TL32711) is a potent, bivalent SMAC mimetic that
binds with differential affinity to multiple members of the IAP
family including cIAP1, cIAP2, XIAP, and ML-IAP. Birinapant is
differentiated from other SMAC mimetics in that it results in the
selective degradation of cIAP1 bound to TRAF-2 in the TNF receptor
complex, sparing non-TRAF-2 bound cIAP1. This
unique IAP antagonism profile of birinapant may result in the
improved tolerability and therapeutic index observed with this
agent.
About TetraLogic
TetraLogic is a clinical-stage biopharmaceutical company focused
on discovering and developing novel small molecule therapeutics in
oncology and infectious diseases. TetraLogic has two clinical-stage
product candidates in development: birinapant and suberohydroxamic
acid phenyl ester (SHAPE). Birinapant is currently being tested in
Phase 1 and Phase 2 clinical trials for hematological malignancies
and solid tumors. SHAPE is entering Phase 2 trials for early-stage
CTCL.
Forward Looking Statements
Some of the statements in this release are forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, which involve
risks and uncertainties. These statements relate to future events
or TetraLogic's pre-clinical and clinical development of
birinapant, SHAPE and other clinical programs, future expectations,
plans and prospects. Although TetraLogic believes that the
expectations reflected in such forward-looking statements are
reasonable as of the date made, expectations may prove to have been
materially different from the results expressed or implied by such
forward-looking statements. TetraLogic has attempted to identify
forward-looking statements by terminology including ''believes,''
''estimates,'' ''anticipates,'' ''expects,'' ''plans,''
''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,''
''might,'' ''will,'' ''should,'' ''approximately'' or other words
that convey uncertainty of future events or outcomes to identify
these forward-looking statements. These statements are only
predictions and involve known and unknown risks, uncertainties, and
other factors, including those discussed under the heading "Risk
Factors" in our Annual Report on Form 10-K filed with the
Securities and Exchange Commission on March 19, 2014 and our
Quarterly Report of Form 10-Q filed with the Securities and
Exchange Commission on May 8, 2014. Any forward-looking statements
contained in this release speak only as of its date. We undertake
no obligation to update any forward-looking statements contained in
this release to reflect events or circumstances occurring after its
date or to reflect the occurrence of unanticipated events.
CONTACT: Company Contact:
Pete A. Meyers
Chief Financial Officer and Treasurer
TetraLogic Pharmaceuticals Corporation
(610) 889-9900, x103
pete.meyers@tlog.com
Investor Relations Contact:
Ami Bavishi
Burns McClellan, Inc.
(212) 213-0006
abavishi@burnsmc.com
TetraLogic Pharmaceuticals (CE) (USOTC:TLOG)
Historical Stock Chart
From Jun 2024 to Jul 2024
TetraLogic Pharmaceuticals (CE) (USOTC:TLOG)
Historical Stock Chart
From Jul 2023 to Jul 2024